Citigroup
TXMD icon

Citigroup’s TherapeuticsMD TXMD Stock Holding History

Citigroup’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,706
Closed -$103K – 7403
2020
Q4 		$103K Buy
1,706
+250
+17% +$17.1K ﹤0.01% 5512
2020
Q3 		$115K Sell
1,456
-322
-18% -$25.7K ﹤0.01% 5013
2020
Q2 		$111K Buy
1,778
+124
+7% +$7.22K ﹤0.01% 5498
2020
Q1 		$88K Sell
1,654
-594
-26% -$58.9K ﹤0.01% 5454
2019
Q4 		$272K Buy
2,248
+674
+43% +$96.9K ﹤0.01% 4924
2019
Q3 		$286K Buy
1,574
+662
+73% +$93.3K ﹤0.01% 4854
2019
Q2 		$119K Sell
912
-128
-12% -$22.9K ﹤0.01% 5715
2019
Q1 		$253K Buy
1,040
+362
+53% +$95.8K ﹤0.01% 4868
2018
Q4 		$129K Sell
678
-78
-10% -$19K ﹤0.01% 5436
2018
Q3 		$248K Sell
756
-260
-26% -$79.7K ﹤0.01% 5024
2018
Q2 		$317K Buy
1,016
+584
+135% +$178K ﹤0.01% 4575
2018
Q1 		$105K Sell
432
-34
-7% -$9.54K ﹤0.01% 5574
2017
Q4 		$141K Buy
466
+464
+23,200% +$129K ﹤0.01% 5337
2017
Q3 		$1K Buy
+2
New +$578 ﹤0.01% 7160

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's TXMD Position: Q1 2026 in Review

Citigroup sold out of TherapeuticsMD (TXMD) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in TXMD in Q2 2013 and held it in 40 quarters. The position peaked at $1.56M in Q1 2021. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Citigroup reported no remaining TherapeuticsMD position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 TherapeuticsMD share in Q1 2026, an estimated $2.
  • Citigroup first reported a position in TherapeuticsMD in Q2 2013 and held it in 40 quarters.
  • Citigroup's TherapeuticsMD position peaked at $1.56M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.